PIPAC + Nab-paclitaxel for Pancreatic Cancer

This trial tests a new method of delivering chemotherapy directly into the abdomen for individuals with pancreatic cancer that has spread only to the abdominal lining. The goal is to determine if this approach can improve quality of life and extend survival by targeting treatment precisely while minimizing side effects. It suits those diagnosed with pancreatic cancer confined to the abdomen who are not candidates for more aggressive surgery. This method uses Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) combined with Nab-paclitaxel, a chemotherapy drug. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative approach.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

A previous study found PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) to be generally safe. Researchers used it with drugs like cisplatin and doxorubicin, and no major safety issues arose. Another report indicated that only 6.2% of patients experienced serious complications with PIPAC, which is quite low, suggesting it is well-tolerated.

For nab-paclitaxel, commonly used for pancreatic cancer, research has shown that some patients may experience side effects like low white blood cell count, low red blood cell count, and nerve damage. However, nab-paclitaxel is already approved for treating pancreatic cancer when used with gemcitabine, indicating it is considered safe for this purpose.

Unlike the standard treatments for pancreatic cancer, which typically involve systemic chemotherapy like FOLFIRINOX or gemcitabine with nab-paclitaxel, PIPAC + nab-paclitaxel offers a unique delivery method. PIPAC stands for Pressurized Intraperitoneal Aerosolized Chemotherapy, and it allows chemotherapy to be delivered directly into the abdominal cavity in an aerosolized form. This targeted approach potentially enhances drug penetration into cancerous tissues while minimizing systemic side effects. Researchers are excited because this method could improve efficacy in patients with peritoneal-only metastasis from pancreatic cancer, offering a more localized and potentially more effective treatment option.

This trial will evaluate the safety of combining PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) with nab-paclitaxel for patients with pancreatic cancer that has spread to the abdominal lining. Studies have shown that PIPAC can safely and effectively treat cancers affecting the abdominal lining by delivering chemotherapy directly to the tumor, potentially enhancing drug delivery and reducing side effects. Although limited data exists specifically for pancreatic cancer with abdominal spread, combining nab-paclitaxel with other chemotherapy drugs like gemcitabine has improved survival rates in pancreatic cancer. These treatments have shown promise in enhancing both quality of life and survival for various cancers affecting the abdominal lining.⁶⁷⁸⁹¹⁰